RC,
The market is a forward looking instrument.
The market will value the unique opportunity here...way ahead of revenue!
ATL1102 will be a First in Class + Best in Class drug...protected by ODD for 7 - 10 years.
We are talking $4B per year market just for non-ambulant boys (EU/US).
Say they attain only 50% of the market - that is still $2B per year revenue.
Currently we are sitting at sub $150m market cap.
So...soon we start the value accretion in line with FA progress.
The only way is up...baby...for you and me!
.
Ann: Positive PDCO opinion and A$20m Placement, page-69
-
- There are more pages in this discussion • 98 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 192779 | 7.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 8181 | 1 |
View Market Depth
| Last trade - 07.00am 29/07/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable